Sponsor study identifier
observational
39
1 country
2
Study Start
September 2012
Actual (reported)Primary Completion
December 2017
Actual (reported)Study Completion
February 2018
Actual (reported)The purpose of this study is to measure the presence of HMGB-1 and other proteins in the blood across five time points after stroke, and to determine if their presence correlates with rate of stroke recovery.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
February 2018
Actual (reported)Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 2012
Actual (reported)October 9, 2012
Actual (reported)October 12, 2012
Actual (reported)December 2017
Actual (reported)February 2018
Actual (reported)Cytokine levels (HMGB-1) in plasma samples
day 1, day7, day 14, day 30, day 90
NIH and Rankin Clinical Measures of functional recovery
day 1, day7, day 14, day 30, day 90
Acute care hospital (stroke unit)
North Shore University Hospital
Manhasset, New York, 11030, United States
Long Island Jewish Medical Center
New Hyde Park, New York, 11040, United States
Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey KJ, Bendszus M, Rossetti G, Nawroth PP, Bierhaus A, Schwaninger M. The HMGB1 receptor RAGE mediates ischemic brain damage. J Neurosci. 2008 Nov 12;28(46):12023-12031. doi: 10.1523/JNEUROSCI.2435-08.2008.
Goldstein RS, Gallowitsch-Puerta M, Yang L, Rosas-Ballina M, Huston JM, Czura CJ, Lee DC, Ward MF, Bruchfeld AN, Wang H, Lesser ML, Church AL, Litroff AH, Sama AE, Tracey KJ. Elevated high-mobility group box 1 levels in patients with cerebral and myocardial ischemia. Shock. 2006 Jun;25(6):571-4. doi: 10.1097/01.shk.0000209540.99176.72.
Whole blood, DNA, serum/serum cytokines
Bruce T Volpe, MD
Feinstein Institute for Medical Research
39 participants (actual enrollment reported by the registry).
First Submitted
October 9, 2012
First Posted
October 12, 2012
Study Start
September 2012
Actual (reported)Fabry and Stroke Epidemiological Protocol (FASEP): Risk Factors In Ischemic Stroke Patients With Fabry Disease
Contact the study team to confirm eligibility.
Primary Completion
December 2017
Actual (reported)Study Completion
February 2018
Actual (reported)Last Updated
March 12, 2018
Record last verified: 2018-02
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: